論文・総説（英文）

2024

261.: Yoshimoto M. Jin D, Sakonjo H, Takai S. Renal protective effects of chymase inhibition on cisplatin-induced nephrotoxicity in mice. Bulletin OMPU, in press.
260.

260.: Shimada K , Hirose M, Hamabe L, Takai S, Jin D, Yilmaz Z, Kocaturk M, Tanaka R. Evaluation of alacepril administration in canine patent ductus arteriosus according to plasma chymase activity. Animals 14, 1078, 2024.

2023

259.: Ishigooka G, Mizuno H, Oosuka S, Jin D, Takai S, Kida T. Effects of angiotensinreceptor blockers on streptozotocin-induced diabetic cataracts. J Clin Med. 12(20), 6627, 2023.

258.: Kumagai E, Furumachi K, Kurihara A, Hosokawa K, Hosohata K, Takai S. Zinc acetate hydrate supplementation versus polaprezinc supplementation for improving hypozincemia in hemodialysis patients: a randomized clinical trial. Int J Nephrol. 2403755, 1-11, 2023.

257.: Nuri T, Jin D, Takai S, Ueda K. Tryptase-positive mast cells promote adipose fibrosis in secondary lymphedema through PDGF. Curr Issues Mol Biol. 45(10), 8027-8039, 2023.

256.: Fukiyama Y, Hirokawa T, Takai S, Kida T, Oku H. Involvement of glycogen synthase kinase 3β (GSK3β) in formation of phosphorylated tau and death of retinal ganglion cells of rats caused by optic nerve crush. Curr Issues Mol Biol. 45(9), 6941-6957, 2023.

255.: Nishimura H, Jin D, Kinoshita I, Taniuchi M, Higashino M, Terada T, Takai S, Kawata R. Increased chymase-positive mast cells in high-grade mucoepidermoid carcinoma of the parotid gland. Int J Mol Sci. 24(9), 8267, 2023.

254.: Lapointe C, Vincent L, Giguère H, Auger-Messier M, Schwertani A, Jin D, Takai S, Pejler G, Sirois MG, Tinel H, Heitmeier S, D'Orléans-Juste P. Chymase inhibition resolves and prevents deep vein thrombosis without increasing bleeding time in the mouse model. J Am Heart Assoc.12(4), e028056, 2023.

2022

253.: Shimada K, Hamabe L, Hirose M, Watanabe M, Yokoi A, Takeuchi A, Ozai Y, Yoshida T, Takai S, Jin D, Kocaturk M, Uehara K, Tanaka R. Plasma chymase activity reflects the change in hemodynamics observed after the surgical treatment of patent ductus arteriosus in dogs. Vet Sci. 9(12), 682, 2022.

252.: Takai S, Jin D. Pathophysiological Role of Chymase-Activated Matrix Metalloproteinase-9. Biomedicines. 10(10), 2499, 2022. (Review)

251.: Inomata Y, Oh JW, Jin D, Taniguchi K, Sugito N, Kawaguchi N, Hirokawa F, Lee SW, Akao Y, Takai S. Kim KP, Uchiyama K. miR-122-5p downregulation activities glycolysis via PKM2 in Kupper cells of rat and mouse models of non-alcoholic steatohepatitis. Int J Mol Sci. 23(9), 5230, 2022.

250.: Yoneyama H, Hosohata K, Jin D, Yoshida I, Toyoda M, Kitamura I, Takai S. Usami Y. Design, synthesis, and evaluation of new vanin-1 inhibitors based on RR6. Bioorg Med Chem, 65, 116791, 2022.

249.: Kumagai E, Hosohata K, Furumachi K, Takai S. Range of serum transthyretin levels in hemodialysis patients at a high risk of one-year mortality: a retrospective cohort study. Ther Apher Dial. 26(4), 743-748, 2022.

248.: Fujita Y, Jin D, Mimura M, Sato Y, Takai S, Kida T. Activation of mast cell-derived chymase in the lacrimal glands of patients with IgG4-related ophthalmic disease Int J Mol Sci. 23(5), 2556, 2022.

2021

247.: Hosohata K, Jin D, Takai S. Glaucocalyxin A ameliorates hypoxia/reoxygenation-induced injury human renal proximal tubular epithelial cell line HK-2cells. Int J Mol Sci. 23(1), 446, 2021.

246.: Kinoshita I, Jin D, Higashino M, Terada T, Kurisu Y, Takai S, Kawata R. Increase of chymase-positive mast cells in reccurent pleo-morphic adenoma and carcinoma expleomorphic adenoma of the parotid gland. Int J Mol Sci. 22(23), 12613, 2021.

245.: Kuramoto T, Jin D, Komeda K, Taniguchi K, Hirokawa F, Takai S, Uchiyama K. Chymase as a novel therapeutic target in acute pancreatitis. Int J Mol Sci. 22(22), 12313, 2021.

244.: Hosohata K, Jin D, Takai S. In vivo and in vitro evaluation of urinary biomarkers in ischemia/reperfusion-induced kidney injury. Int J Mol Sci. 22(21), 11448, 2021.

243.: Hirokawa T, Horie T, Fukiyama Y, Mimura M, Takai S, Kida T, Oku H. Roscovitine, a cyclin dependent kinase-5 inhibitor, decreases phosphorylated tau formation and death of retinal ganglion cells of rats after optic nerve crush. Int J Mol Sci. 22(15), 8096, 2021.

242.: Ikeda T, Nakamura K, Morishita S, Sato T, Horie T, Kida T, Oku H, Takai S, Jin D. Decreased presence of mast cell in the bursa premacularis of proliferative diabetic retinopathy. Ophthalmic Res. 64(6), 1002-1012, 2021.

241.: Kumagai E, Hosohata K, Furumachi K, Takai S. Effectiveness of monitoring free carnitine levels for L-carnitine supplementation in hemodialysis patients to maintain carnitine sufficiency and nutritional factors. Ther Apher Dial. 25(5), 595-606, 2021.

240.: Yoshizaki Y, Nagata T, Fujiwara S, Takai S, Jin D, Kuzuya M, Ohya Y. Postoperative adhesion prevention using a biodegradable temperature-responsive injectable polymer system and concomitant effects of chymase inhibitor. ACS Appl Bio Mater. 4(4), 3079-3088, 2021.

239.: Morishita S, Sato T, Oosuka S, Horie T, Kida T, Oku H, Nakamura K, Takai S, Jin D, Ikeda T. Expression of lymphatic markers in the Berger's space and bursa premacularus. Int J Mol Sci. 22(4), 2086, 2021.

238.: Vincent L, Lapointe C, Lo M, Gagnon H, Pejler G, Takai S, Day R, D'Orleans-Juste P. Mast cell degranulation increases mast cell protease 4-dependent vasopressor responses to big endothelin-1 but not angiotensin I. J Pharmacol Exp Ther. 376(2), 213-221, 2021.

2020

237.: Shibayama Y, Takahashi K, Yamaguchi H, Yasuda J, Yamazaki D, Rahman A, Fujimori T, Fijisawa Y, Takai S, Furukawa T, Nakagawa T, Ohsaki H, Kobara H, Wong J, Masaki T, Yuzawa Y, Kiyomoto H, Yachida S, Fujimoto A, Nishiyama A. Aberrant (Pro)renin receptor expression induces genomic instability in pacreatic ductal adenocaricinma through upregulation of SMARCA5/SNF2H. Commun Biol. 3(1), 724, 2020.

236.: Takai S, Jin D. Chymase as a possible therapeutic target for amelioration of non-alcoholic steatohepatitis. Int J Mol Sci. 21(20), 7543, 2020. (Review)

235.: Terai K, Jin D, Watase K, Imagawa A, Takai S. Mechanism of albuminuria reduction by chymase inhibition in diabetic mice. Int J Mol Sci. 21(20), 7495, 2020.

234.: Mizuno H, Fukumoto M, Sato T, Horie T, Kida T, Oku H, Nakamura K, Jin D, Takai S, Ikeda T. Immunohistological study of human retnal lattice degeneration. Int J Mol Sci. 21(19), 7347, 2020.

233.: Kumagai E, Hosohata K, Furumachi K, Takai S. Range of plasma brain matriuretic peptide (BNP) levels in hemodialysis patents at a high risk of 1-year mortality and their relationship with the natritional status: a retrospective cohort study in one institute. Renal Replacement Therapy. 6, 32, 2020.

232.: Liu S, Liu L, Jin D, Zhang Q, Takai S. A novel mechanism of valproate for prevention of peritoneal adhesion formation. Surg Today. 50(9), 1091-1098, 2020.

231.: Watase K, Jin D, Terai K, Kanemiya T, Nakakura H, Shibahara N, Arima S, Takai S. Possible roles of periostin in the formation of hemodialysis vascular access stenosis after polytetrafluoroethylene graft implantation in dogs. Int J Mol Sci. 21(9), 3251, 2020.

230.: Hirahara I, Kusano E, Jin D, Takai S. Hypermetabolism of glutathione, glutamate and ornithine via redox imbalance in methylglyoxal-induced peritoneal injury rats. J Biochem. 167(2), 185-194, 2020.

2019

229.: Nemoto E, Kojima S, Sugiyama T, Jin D, Takai S, Maeda M, Kohmoto R, Ueki M, Oku H, Ikeda T. Effects of regorafenib, a multi-kinase inhibitor, on conjunctival scarring in a canine filtration surgery model in comparison with mitomycin-C. Int J Mol Sci. 20(1), 63, 2019.

228.: Bivona BJ, Takai S, Seth DM, Satou R, Harrison-Bernard LM. Chymase inhibition retards albuminuria in type 2 diabetes. Physiol Rep. 7(24), e14302, 2019.

227.: Li W, Jin D, Takai S, Hayakawa T, Ogata J, Yamanishi K, Yamanishi H, Okamura H. Impaired function of aorta and perivascular adipose tissue in IL-18-deficient mice. Am J Physiol Heart Circ Physiol. 317(5), H1142-H1156, 2019.

226.: Hosohata K, Jin D, Takai S, Iwanaga K. Involvement of vanin-1 in ameliorating effect oxidative renal tubular injury in Dahl-salt sensitive rats. Int J Mol Sci. 20(18), 4481, 2019.

225.: Teranishi Y, Jin D, Takano S, Sunami K, Takai S. Decrease in number of mast cells in resected nasal polyps as an indicator for postoperative recurrence of chronic rhinosinusitis. Immun Inflamm Dis. 7(3), 191-200, 2019.

224.: Nakao K, Fujiwara A, Komasawa N, Jin D, Kitano M, Matsunami S, Takai S, Ito S, Minami T. Yokukansan alleviates cancer pain by suppressing matrix metalloproteinase-9 in a mouse bone metastasis model. Evid Based Complement Alternat Med. 2019, 2956920, 2019.

223.: Ikeda T, Nakamura K, Oku H, Horie T, Kida T, Takai S. Immunohistological study of monkey foveal retina. Sci Rep. 9(1), 5258, 2019.

222.: Sato T, Morishita S, Horie T, Fukumoto M, Kida T, Oku H, Nakamura K, Takai S, Jin D, IKeda T. Involvement of premacular mast cells in the pathogenesis of macular diseases. PLoS One. 14(2), e0211438, 2019.

221.: Ozeki M, Jin D, Miyaoka M, Masubuchi S, Hirolawa F, Hayashi M, Takai S, Uchiyama K. Comparison of a chymase inhibitor and hyaluronic acid/carboxymethylcellulose (Seprafilm) in a novel peritoneal adhesion model in rats. PLoS One. 14(1), e0211391, 2019.

220.: Jin D, Takai S, Nonaka Y, Yamazaki S, Fujiwara M, Nakamura Y. A chymase inhibitory RNA aptamer improves cardiac function and survival after myocardial infarction. Mol Ther Nucleic Acids. 14, 41-51, 2019.

2018

219.: Okuda Y, Fukumoto M, Horie T, Oku H, Takai S, Nakanishi T, Matsuzaki K, Tsujimoto H, Ikeda T. Periocular injection of candesartan-PLGA microparticles inhibits laser-induced experimental choroidal neovascularization. Clin Ophthal. 13, 87-93, 2018.

218.: Hosohata K, Jin D, Takai S, Iwanaga K. Vanin-1 in the renal pelvic urine reflects kidney injury in a rat model of hydronephrosis. Int J Mol Sci. 19(10), 3186, 2018.

217.: Houde M, Schwertani A, Desbiens L, Toil H, Sarrhini O, Lectome R, Lepage M, Gagnon H, Takai S, Pejler G, Gobeil FJ, Jacques D, Day R, D'Orléans-Juste P. Mouse mast cell protease 4 deletion protects heart function and survival after permanent myocardial infarction. Front Pharmacol. 9, 868, 2018.

216.: Miyaoka Y, Jin D, Tashiro K, Masubuchi S, Ozeki M, Hirokawa F, Hayashi M, Takai S, Uchiyama K. A novel hamster nonalcoholic steatohepatitis model induced by a high-fat and high cholesterol diet. Exp Anim. 67(2), 239-247, 2018.

215.: Takai S, Jin D. Chymase inhibitor as a novel therapeutic agent for non-alcoholic steatohepatitis. Front Pharmacol. 9, 144, 2018. (Review)

214.: Washino S, Hosohata K, Jin D, Takai S, Miyagawa T. Early urinary biomarkers of renal tubular damage by a high-salt intake independent of blood pressure in normotensive rats. Clin Exp Pharmacol Physiol. 45(3), 261-268, 2018.

2017

213.: Maeda M, Kojima S, Sugiyama T, Jin D, Takai S, Oku H, Kohmoto R, Ueki M, Ikeda T. Effects of gelatin hydrogel containing anti-transforming growth factor-β antibody in a canine filtration surgery model. Int J Mol Sci. 18(5), 985, 2017.

212.: Miyaoka Y, Jin D, Tashiro K, Komeda K, Masubuchi S, Hirokawa F, Hayashi M, Takai S, Uchiyama K. Chymase inhibitor prevents the development and progression of non-alcoholic steatohepatitis in rats fed a high-fat and high-cholesterol diet. J Pharmacol Sci. 134(3), 139-146, 2017.

211.: Takai S, Yoshino M, Takao K, Yoshikawa T, Jin D. Periostin antisense oligonucleotide prevents adhesion formation after surgery in mice. J Pharmacol Sci. 133(2), 6-12, 2017.

2016

210.: Tajiri K, Sugiyama T, Katsumura K, Jin D, Takai S, Shimizu K, Ikeda T. Suppression of conjunctival scarring by chymase inhibitor in a canine symblepharon model. Int J Ophthalmol Eye Res. S7-002, 6-12, 2016.

209.: Li W, Jin D, Hata M, Takai S, Yamanishi K, Shen W, El-Darawish, Yamanishi H, Okamura H. Dysfunction of mitochondria and deformed gap junctions in the heart of IL-18-deficient mice. Am J Physiol-Heart Circul Physiol. 311(2), H313-H325, 2016.

208.: Takai S, Jin D. Improvement of cardiovascular remodeling by chymase inhibitor. Clin Exp Pharmacol Physiol. 43(4), 387-393, 2016. (Review)

207.: Takai S, Sakonjo H, Jin D. Comparison of the relative importance of vascular and plasma drug concentrations to the hypertensive effect of telmisartan in rats. J Renin Angiotensin Aldosterone Syst. 17(1), 147032031663895, 2016.

2015

206.: Osumi W, Jin D, Imai Y, Tashiro K, Li ZL, Otsuki Y, Maemura K, Komeda K, Hirokawa F, Hayashi M, Takai S, Uchiyama K. Recombinant human soluble thrombomodulin improved lipopolysaccharide/D-galactosamine-induced acute liver failure in mice. J Pharmacol Sci. 129(4), 233-239, 2015.

205.: Kojima S, Sugiyama T, Takai S, Jin D, Ueki M, Oku H, Ikeda T. Effects of repasudil, a Rho-associated protein kinase inhibitor, on conjunctival scarring in a canine filtration surgery model. Curr Topic Pharmacol. 19, 67-73, 2015.

204.: Ikeda T, Nakamura K, Oku H, Morishita S, Fukumoto M, Suzuki H, Kida T, Horie T, Sugiyama T, Takai S. The role of Tryptase and anti-type II collagen antibodies in the pathogenesis of idiopathic epiretinal membranes. Clin Ophthalmol. 9, 1181-1188, 2015.

203.: Kojima S, Sugiyama T, Takai S, Jin D, Ueki M, Oku H, Tabata Y, Ikeda T. Effects of gelatin hydrogel loading mitomycin C on conjunctival scarring in a canine filtration surgery model. Invest Ophthalmol Vis Sci. 56(4), 2601-2606, 2015.

202.: Semaan W, Desbiens L, Houde M, Labonté J, Gagnon H, Yamamoto D, Takai S, Laidlaw T, Bkaily G, Schwertani A, Pejler G, Levesque C, Desjardins R, Day R, D'Orléans-Juste P. Chymase inhibitor-sensitive synthesis of endothelin-1 (1-31) by recombinant mouse mast cell protease 4 and human chymase. Biochem Pharmacol. 94(2), 91-100, 2015.

2014

201.: Suzuki H, Oku H, Horie T, Morishita S, Tonari M, Oku K, Okubo A, Kida T, Mimura M, Fukumoto M, Kojima S, Takai S, Ikeda T. Changes in expression of aquaporin-4 and aquaporin-9 in optic nerve after crushing in rats. PLoS One. 9(12), e114694, 2014.

200.: Takai S, Sakonjo H, Jin D. Significance of vascular dipeptidyl peptidase-4 inhibition on vascular protection in Zucker diabetic fatty rats. J Pharmacol Sci. 125(4), 386-393, 2014.

199.: Takai S, Jin D, Chen H, Li W, Yamamoto H, Yamanishi K, MiyazakiM, Higashino H, Yamanishi H, Okamura H. Chymase inhibition improves vascular dysfunction and survival in stroke-prone spontaneously hypertensive rats. J Hypetens. 32(8), 1637-1648, 2014.

198.: Yoshida S, Takeuchi T, Kotani T, Yamamoto N, Hata K, Nagai K, Shoda T. Takai S, Makino S, Hanafusa T. Infliximab, a TNF-α inhibitor, reduces 24-hour ambulatory blood pressure in rheumatoid arthritis patients. J Hum Hypertens. 28(3), 165-169, 2014.

197.: Imai Y, Takai S, Jin D, Komeda K, Tashiro K, Li ZL, Otuski Y, Okamura H, Hayashi M. Uchiyama K. Chymase inhibition attenuates lipopolysaccharide/D-galactosamine-induced acute liver failure in hamsters. Pharmacology. 93(1-2), 47-56, 2014.

196.: Morishita S, Oku H, Horie T, Tonari M, Kida T, Sugiyama T, Takai S, Hara H, Ikeda T. Systemic simvastatin rescues retinal ganglion cells from optic nerve injury possibly through suppression of astroglial NF-κB activation. PLoS One. 9(1), e84387, 2014.

2013

195.: Yamamoto D, Takai S, Lindsey ML. Mechanisms and pharmacological implications of MMP-9 inhibition by ACE inhibitor. Medical Uses, Mechanisms of Action, Potential Adverse Effects and Related Topics (Nova publishers) 1, 179-198, 2013. (Review).

194.: Takai S, Jin D, Sakonjo H, Takubo T, Nakanishi T. Significance of the vascular concentration of angiotensin II-receptor blockers on the mechanism of lowering blood pressure in spontaneously hypertensive rats. J Pharmacol Sci. 123(4), 371-379, 2013.

193.: Sugiyama T, Lee SY, Horie T, Takai S, Oku H, Tanioka H, Kuriki Y, Kojima S, Ikeda T. P2X7 receptor activation may be involved in neuronal loss in the retinal ganglion cell layer after acute elevation of intraocular pressure in rat. Mol Vis. 19, 2080-2091, 2013.

192.: Takai S, Jin D, Li ZL, Otsuki Y, Miyazaki M. Significance of matrix metalloproteinase-9 inhibition by imidapril for prevention of abdominal aortic aneurysms in angiotensin II type 1 receptor knockout mice. J Pharmacol Sci. 123(2), 185-194, 2013.

191.: Nabe T, Kijitani Y, Kitagawa Y, Sakano E, Ueno T, Fujii M, Nakao S, Sakai M, Takai S. Involvement of chymase in allergic conjunctivitis of guinea pigs. Exp Eye Res. 113, 74-79, 2013.

190.: Nakanishi T, Takai S, Jin D, Takubo T. Quantification of candesartan in mouse plasma by MALDI-TOFMAS and in tissue sections by MALDI-imaging Using the stable-isotope dilution technique: Mass Spect. 2, A0021(1-6), 2013.

189.: Houde M, Jamain MD, Labonte J, Desbiens L, Pejler G, Gurish M, Takai S, D'Orleans-Juste P. Pivotal role of mouse mast cell protease 4 in the conversion and pressor properties of big endothelin-1. J Pharmacol Exp Ther. 346(1), 31-37, 2013.

188.: Masubuchi S, Komeda K, Takai S. Jin D, Tashiro K, Li ZL, Otsuki Y, Okamura H, Hayashi M, Uchiyama K. Chymase inhibition attenuates monocrotaline-induced sinusoidal obstruction syndrome in hamsters. Curr Med Chem. 20(21), 2723-2729, 2013.

187.: Masubuchi S, Takai S. Jin D, Tashiro K, Komeda K, Li ZL, Otsuki Y, Okamura H, Hayashi M, Uchiyama K. Chymase inhibitor ameliorates hepatic steatosis and fibrosis on established non-alcoholic steatohepatitis in hamsters fed a methionine- and choline-deficient diet. Hepetol Res. 43(9), 970-978, 2013.

186.: Takai S, Jin D, Aritomi S, Niinuma K, Miyazaki M. Hypertens Res. Powerful vascular protection by combining cilnidipine with valsartan in stroke-prone, spontaneously hypertensive rats. Hypertens Res. 36(4), 342-348, 2013.

185.: Fujisaka T, Hoshiga M, Hotchi J, Takeda Y, Jin D, Takai S, Hanafusa T, Ishizaka N. Angiotensin II promotes aortic valve thickening independent of elevated blood pressure in apolipoprotein-E deficient mice. Atherosclerosis. 226(1), 82-87, 2013.

2012

184.: Yamamoto D, Takai S, Akimoto T, Hirahara I, Ito C, Muto S, Kusano E. Matrix metalloproteinase-2 inhibition by temocapril and its important role in peritoneal transport. Clin Exp Pharmacol Physiol. 39(10), 864-868, 2012.

183.: Matsuno K, Iwata K, Matsumoto M, Katsuyama M, Cui W, Murata A, Nakamura H, Ibi M, Ikami K, Zhang J, Matoba S, Jin D, Takai S, Matsubara H, Matsuda N, Yabe-Nishimura C. NOX1/NADPH oxidase is involved in endotoxin-induced cardiomyocyte apoptosis. Free Radical Biol Med. 53(9), 1718-1728, 2012.

182.: Kotani T, Takeuchi T, Takai S, Yoshida S, Makino S, Hanafusa T. Serum levels of matrix metalloproteinase (MMP) 9, a risk factor for acute coronary syndrome, are reduced independently of serum MMP-3 by anti-TNF-α antibody (infliximab) therapy in patients with rheumatoid arthritis. J Pharmacol Sci. 120(1), 50-53, 2012.

181.: Sarukura N, Takai S, Ikemoto S, Korin T, Ueda Y, Kitamura Y, Kalubi B, Yamamoto S, Takeda N. Effects of dietary zinc deprivation on zinc concentration and ratio of apo/holo-activities of angiotensin converting enzyme in serum of mice. Auris Nasus Larynx. 39(3), 294-297, 2012.

180.: Okui S, Yamamoto H, Lib W, Gamachi N, Fujita Y, Kashiwamura S, Miura D, Takai S, Miyazaki M, Urade M, Okamura H, Ueda H. Cisplatin-induced acute renal failure in mice is mediated by chymase-activated angiotensin-aldosterone system and interleukin-18. Eur J Pharmacol. 685(1-3), 149-155, 2012.

179.: Jin D, Takai S, Li Z, Sakonjo H, Otsuki Y, Shibayama Y, Miyazaki M. Outside fibroblasts play a key role in the development of inner neointima after the implantation of PTFE grafts. J Pharmacol Sci. 119(2), 139-149, 2012.

178.: Takai S, Jin D, Miyazaki M. Multiple mechanisms for the action of chymase inhibitors. J Pharmacol Sci. 118(3), 311-316, 2012. (Review)

2011

177.: Sarukura N, Kogirima M, Takai S, Kitamura Y, Kalubi B, Yamamoto S, Takeda N. Dietary zinc intake and its effects on zinc nutrition in healthy Japanese living in the central area of Japan. J Med Invest. 58(3-4), 203-209, 2011.

176.: Kojima S, Sugiyama T, Takai S, Jin D, Shibata M, Oku H, Tabata Y, Ikeda T. Effects of gelatin hydrogel containing chymase inhibitor on scarring in a canine filtration surgery model. Invest Ophth Vis Sci. 52(10), 7672-7680, 2011.

175.: Oyamada S, Bianchi C, Takai S, Chu LM, Sellke FW. Chymase inhibition reduces infarction and matrix metalloproteinase-9 activation and attenuates inflammation and fibrosis acute myocardial ischemia/reperfusion. J Pharmacol Exp Ther. 339(1), 143-151, 2011.

174.: Takai S, Jin D, Miyazaki M. Irbesartan prevents metabolic syndrome in rats via activation of peroxisome proliferator-activated receptorγ J Pharmacol Sci. 116(3), 309-315, 2011.

173.: Takai S, Jin D, Sakonjo H, Shimosato T, Miyazaki M. Candesartan and amlodipine combination therapy provides powerful vascular protection in stroke-prone spontaneously hypertensive rats. Hypertens Res. 34(2), 245-252, 2011.

172.: Takai S, Jin D, Miyazaki M. Targets of chymase inhibitors. Expert Opin Ther Targets. 15(4), 519-527, 2011. (Review)

2010

171.: Kakimoto K, Takai S, Murano M, Ishida K, Yoda Y, Inoue T, Jin D, Umegaki E, Higuchi K. Significance of chymase-dependent matrix metalloproteinase-9 activation on indomethacin-induced small intestinal damages in rats. J Pharmacol Exp Ther. 332(2), 684-689, 2010.

170.: Tashiro K, Takai S, Jin D, Yamamoto H, Komeda K, Hayashi M, Tanaka K, Tanigawa N, Miyazaki M. Chymase inhibitor prevents the nonalcoholic steatohepatitis in hamsters fed a methionine- and choline-deficient diet. Hepatol Res. 40(5), 514-523, 2010.

169.: Takai S, Jin D, Sakonjo H, Miyazaki M. Combination therapy with irbesartan and efonidipine for attenuation of proteinuria in Dahl salt-sensitive rats. Hypertens Res. 33(9), 953-959, 2010.

168.: Oyamada S, Bianchi C, Takai S, Robich MP, Clement RT, Chu L, Sellke F. Impact of acute myocardial ischemia reperfusion on the tissue and blood-born renin-angiotensin system. Basic Res Cardiol. 105(4), 513-522, 2010.

167.: Komeda K, Takai S, Jin D, Tashiro K, Hayashi M, Tanigawa N, Miyazaki M. Chymase inhibition attenuates tetrachloride-induced liver fibrosis in hamsters. Hepatol Res. 40(8), 832-840, 2010.

166.: Yamamoto D, Takai S, Hirahara I, Kusano E. Captopril directly inhibits matrix metalloproteinase-2 activity in continuous ambulatory peritoneal dialysis therapy. Clin Chim Acta. 411(9-10), 762-764, 2010.

165.: Inoue N, Takai S, Jin D, Okumura K, Okamura N, Kajiura M, Yoshikawa S, Kawamura N, Tamai H, Miyazaki M. Effect of angiotensin converting enzyme inhibitor on matrix metalloproteinase-9 activity in patients with Kawasaki disease. Clin Chim Acta. 411(3-4), 267-269, 2010.

164.: Takai S, Jin D, Miyazaki M. Chymase as an important target for preventing complications of metabolic syndrome. Curr Med Chem. 17(28), 3223-3229, 2010. (Review)

163.: Takai S, Jin D, Miyazaki M. New approaches to blockade of the renin-angiotensin-aldosterone system: chymase as an important target to prevent organ damage. J Pharmacol Sci. 113(4), 301-309, 2010. (Review)

162.: Hayashi T, Takai S, Yamashita C. Impact of the renin-angiotensin-aldosterone-system on cardiovascular and renal complications in diabetes mellitus. Curr Vasc Pharmacol. 8(2), 189-197, 2010. (Review)

2009

161.: Okada K. Sugiyama T, Takai S, Jin D, Ishida O, Fukumoto M, Oku H, Miyazaki M, Ikeda T. Effects of mitomycin C on the expression of chymase and mast cells in the conjunctival scar of a monkey trabeculectomy model. Mol Vis. 15, 2029-2036, 2009.

160.: Guma M, Ronacher L, Liu-Bryan R, Takai S, Karin M, Corr M. Caspase 1-independent activation of interleukin-1β in neutrophil-predominant inflammation. Arthritis Rheim. 60(12), 3642-3650, 2009.

159.: Matsumoto C, Hayashi T, Kitada K, Yamashita C, Miyamura M, Mori T, Ukimura A, Ohkita M, Jin D, Takai S, Miyazaki M, Okada Y, Kitaura Y, Matsumura Y. Chymase plays an important role in left ventricular remodeling induced by intermittent hypoxia in mice. Hypertension. 54(1), 164-171, 2009.

158.: Takai S, Jin D, Ikeda H, Sakonjo H, Miyazaki M. Significance of angiotensin II receptor blockers with high affinity to angiotensin II type 1 receptors for vascular protection in rats. Hypertens Res. 32(10), 853-860, 2009.

157.: Amano N, Takai S, Jin D, Ueda K, Miyazaki M. Possible roles of mast cell-derived chymase for skin rejuvenation. Laser Med Sci. 24(2), 223-229, 2009.

156.: Takai S, Jin D, Ohzu M, Tanaka T, Miyazaki M. Chymase inhibition provides pancreatic islet protection in hamsters with streptozotocin-induced diabetes. J Pharmacol Sci. 110(4), 459-465, 2009.

155.: Takai S, Jin D, Kawashima H, Kimura M, Shiraishi-Tateishi A, Tanaka T, Kakutani S, Tanaka K, Kiso Y, Miyazaki M. Anti-atherosclerotic effects of dihomo-γ-linolenic acid in apoE-deficient mice. J Atheroscler Thromb. 16(4), 480-489, 2009.

154.: Inoue N, Muramatsu M, Jin D, Takai S, Hayashi T, Katayama H, Kitaura Y, Tamai H, Miyazaki M. Involvement of vascular angiotensin II-forming enzymes in the progression of aortic abdominal aneurysms in angiotensin II-infused apoE-deficient mice. J Atheroscler Thromb. 16(3), 164-171, 2009.

153.: Inoue N, Muramatsu M, Jin D, Takai S, Hayashi T, Katayama H, Kitaura Y, Tamai H, Miyazaki M. Effects of chymase inhibitor on angiotensin II-induced abdominal aortic aneurysm development in apolipoprotein E-deficient mice. Atherosclerosis. 204(2), 359-364, 2009.

152.: Jin D, Takai S, Sugiyama T, Hayashi T, Fukumoto M, Oku H, Kitaura Y, Ikeda T, Miyazaki M. Long-term angiotensin II blockade may improve not only hyperglycemia but also age-associated cardiac fibrosis. J Pharmacol Sci. 109(2), 275-284, 2009.

151.: Simard E, Jin D, Takai S, Miyazaki M, Brochu I, D'Orléans-Juste P. Chymase-dependent conversion of Big endothelin-1 in the mouse in vivo. J Pharmacol Exp Ther. 328(2), 540-548, 2009.

150.: Yamamoto D, Takai S. Pharmacological implications of MMP-9 inhibition by ACE inhibitors. Curr Med Chem. 16(11), 1349-1354, 2009. (Review)

2008

149.: Yamamoto D, Takai S, Miyazaki M. Inhibitory profiles of captopril on matrix metalloproteinase-9 activity. Eur J Pharmacol. 588(2-3), 277-279, 2008.

148.: Komeda K, Jin D, Takai S, Hayashi M, Takeshita A, Shibayama Y, Tanigawa N, Miyazaki M. Significance of chymase-dependent angiotensin II formation in the progression of human liver fibrosis. Hepatol Res. 38(5), 501-510, 2008.

147.: Shimizu Y, Matsumoto K, Okayama Y, Sakai K, Maeno T, Suga T, Miura T, Takai S, Kurabayashi M, Saito H. Interleukin-3 does not affect the differentiation of mast cells derived from human bone marrow progenitors. Immunol Invest. 37(1), 1-17, 2008.

146.: Konishi Y, Morikawa T, Okada N, Maeda I, Kitabayashi C, Yoshioka K, Okumura M, Nishiyama A, Ueda M, Takai S, Miyazaki M, Imanishi M. Evidence for abundant presence of chymase-positive mast cells in the kidneys of patients with immunoglobulin A nephropathy: effect of combination therapy with prednisolone and angiotensin II receptor blocker valsartan. Hypertens Res. 31(8), 1517-1524, 2008.

145.: Ishida K, Takai S, Murano M, Nishikawa T, Inoue T, Murano N, Inoue N, Jin D, Umegaki E, Higuchi K, Miyazaki M. Role of chymase-dependent matrix metalloproteinase-9 activation in mice with dextran sodium sulfate-induced colitis. J Pharmacol Exp Ther. 324(2), 422-426, 2008.

144.: Kanemitsu H, Takai S, Tsuneyoshi H, Yoshikawa E, Nishina T, Miyazaki M, Ikeda T, Komeda M. Chronic chymase inhibition preserves cardiac function after left ventricular repair in rats. Eur J Cardiothorac Surg. 33(1), 25-31, 2008.

143.: Fukumoto M, Takai S, Ishizaki E, Sugiyama T, Oku H, Jin D, Sakaguchi M, Sakonjo H, Ikeda T, Miyazaki M. Involvement of angiotensin II-dependent vascular endothelial growth factor gene expression via NADPH oxidase in the retina in a type 2 diabetic rat model. Curr Eye Res. 33(10), 885-891, 2008.

142.: Furubayashi K, Takai S, Jin D, Miyazaki M, Katsumata T, Inagaki S, Kimura M, Tanaka K, Nishimoto M, Fukumoto H. Chymase activates promatrix metalloproteinase-9 in human abdominal aortic aneurysm. Clin Chim Acta. 388(1-2), 214-216, 2008.

2007

141.: Takai S, Jin D, Kimura M, Kirimura K, Sakonjo H, Tanaka K, Miyazaki M. Inhibition of vascular angiotensin-converting enzyme by telmisartan via the peroxisome proliferator-activated receptor gamma agonistic property in rats. Hypertens Res. 30(12), 1231-1237, 2007.

140.: Yamamoto D, Takai S, Jin D, Inagaki S, Tanaka K, Miyazaki M. Molecular mechanism of imidapril for cardiovascular protection via inhibition of MMP-9. J Mol Cell Cardiol. 43(6), 670-676, 2007.

139.: Takai S, Jin D, Inagaki S, Yamamoto D, Tanaka K, Miyazaki M. Significance of matrix metalloproteinase-9 in cardiac dysfunction during the very acute phase after myocardial infarction in hamsters. Eur J Pharmacol. 572(1), 57-60, 2007.

138.: Takai S, Yamamoto D, Jin D, Inagaki S, Yoshikawa K, Tanaka K, Miyazaki M. Inhibition of matrix metalloproteinase-9 activity by lisinopril after myocardial infarction in hamsters. Eur J Pharmacol. 568(1-3), 231-233, 2007.

137.: Soga Y, Takai S, Koyama T, Okamoto Y, Ikeda T, Nishimura K, Miyazaki M, Komeda M. Attenuating effects of chymase inhibitor on pericardial adhesion following cardiac surgery. J Cardiac Surg. 22(4), 343-347, 2007.

136.: Matsui A, Okigaki M, Amano K, Adachi Y, Jin D, Takai S, Yamashita T, Kawashima S, Kurihara T, Miyazaki M, Tateishi K, Matsunaga S, Katsume A, Honshou S, Takahashi T, Matoba S, Kusaba T, Tatsumi T, Matsubara H. Central role of calcium-dependent tyrosine kinase PYK2 in endothelial nitric oxide synthase-mediated angiogenic response and vascular function. Circulation. 116(9), 1041-1051, 2007.

135.: Jin D, Ueda H, Takai S, Muramatsu M, Furubayashi K, Ibaraki T, Kishi K, Katsuoka Y, Miyazaki M. Roles of chymase in stenosis occurring after polytetrafluoroethylene graft implantations. Life Sci. 81(16), 1291-1300, 2007.

134.: Tanaka H, Takai S, Jin D, Furubayashi K, Inoue N, Kajimoto Y, Miyatake S, Kuroiwa T, Miyazaki M. Inhibition of matrix metalloproteinase-9 activity by trandolapril after middle cerebral artery occlusion in rats. Hypertens Res. 30(5), 469-475, 2007.

133.: Furubayashi K, Takai S, Jin D, Muramatsu M, Ibaraki T, Nishimoto M, Fukumoto H, Katsumata T, Miyazaki M. The significance of chymase in the progression of abdominal aortic aneurysms in dogs. Hypertens Res. 30(4), 349-357, 2007.

132.: Kishi K, Muramatsu M, Jin D, Furubayashi K, Takai S, Tamai H, Miyazaki M. The effects of chymase on matrix metalloproteinase-2 activation in neointimal hyperplasia after balloon injury in dogs. Hypertens Res. 30(1), 77-83, 2007.

131.: Kusumoto A, Ishikura Y, Kawashima H, Kiso Y, Takai S, Miyazaki M. Effects of arachidonate-enriched triacylglycerol supplementation on serum fatty acids and platelet aggregation in healthy male subjects with a fish diet. Br J Nutr. 98(3), 626-635, 2007.

130.: Hirono Y, Yoshimoto T, Suzuki N, Sugiyama T, Sakurada M, Takai S, Kobayashi N, Shichiri M, Hirata Y. Angiotensin II receptor type 1-mediated vascular oxidative stress and proinflammatory gene expression in aldosterone-induced hypertension: the possible role of local renin-angiotensin system. Endocrinology. 148(4), 1688-1696, 2007.

129.: Yamamoto D, Takai S, Miyazaki M. Prediction of interaction mode between a typical ACE inhibitor and MMP-9 active site. Biochem Biophys Res Commun. 354(4), 981-984, 2007.

128.: Tanaka T, Sohmiya K, Kono T, Terasaki F, Horie R, Ohkaru Y, Muramatsu M, Takai S, Miyazaki M, Kitaura Y. Thiamine attenuates the hypertension and metabolic abnormalities in CD36-defective SHR: uncoupling of glucose oxidation from cellular entry accompanied with enhanced protein O-GlcNAcylation in CD36 deficiency. Mol Cell Biochem. 299(1-2), 23-35, 2007.

127.: Arishiro K, Hoshiga M, Negoro N, Jin D, Takai S, Miyazaki M, Ishihara T, Hanafusa T. Angiotensin receptor-1 blocker inhibits atherosclerotic changes and endothelial disruption of the aortic valve in hypercholesterolemic rabbits. J Am Coll Cardiol. 49(13), 1482-1489, 2007.

2006

126.: Soga Y, Takai S, Okabayashi H, Nagasawa A, Yokota T, Nishimura K, Miyazaki M, Komeda M. Human gastroepiploic artery has greater chymase activity than the internal thoracic artery. Eur J Cardiothorac Surg. 30(6), 877-880, 2006.

125.: Kanemitsu H, Takai S, Tsuneyoshi H, Nishina T, Yoshikawa K, Miyazaki M, Ikeda T, Komeda M. Chymase inhibition prevents cardiac fibrosis and dysfunction after myocardial infarction in rats. Hypertens Res. 29(1), 57-64, 2006.

124.: Kondo K, Muramatsu M, Okamoto Y, Jin D, Takai S, Tanigawa N, Miyazaki M. Expression of chymase-positive cells in gastric cancer and its correlation with the angiogenesis. J Surg Oncol. 93(1), 36-42, 2006.

123.: Sugiyama T, Katsumura K, Nakamura K, Kobayashi M, Muramatsu M, Maruichi M, Oku H, Takai S, Miyazaki M, Ikeda T. Effects of chymase on the macular region in monkeys and porcine muller cells: probable involvement of chymase in the onset of idiopathic macular holes. Ophthalmic Res. 38(4), 201-208, 2006.

122.: Takamiya M, Okigaki M, Jin D, Takai S, Nozawa Y, Adachi Y, Urao N, Tateishi K, Nomura T, Zen K, Ashihara E, Miyazaki M, Tatsumi T, Takahashi T, Matsubara H. Granulocyte colony-stimulating factor-mobilized circulating c-Kit+/Flk-1+ progenitor cells regenerate endothelium and inhibit neointimal hyperplasia after vascular injury. Arterioscler Thromb Vasc Biol. 26(4), 751-757, 2006.

121.: Morihara K, Takai S, Takenaka H, Sakaguchi M, Okamoto Y, Morihara T, Miyazaki M, Kishimoto S. Cutaneous tissue angiotensin-converting enzyme may participate in pathologic scar formation in human skin. J Am Acad Dermatol. 54(2), 251-257, 2006.

120.: Kishi K, Jin D, Takai S, Muramatsu M, Katayama H, Tamai H, Miyazaki M. Role of chymase-dependent angiotensin II formation in monocrotaline-induced pulmonary hypertensive rats. Pediatr Res. 60(1), 77-82, 2006.

119.: Ishizaki E, Takai S, Ueki M, Maeno T, Maruichi M, Sugiyama T, Oku H, Ikeda T, Miyazaki M. Correlation between angiotensin-converting enzyme, vascular endothelial growth factor, and matrix metalloproteinase-9 in the vitreous of eyes with diabetic retinopathy. Am J Ophthalmol. 141(1), 129-134, 2006.

118.: Takai S, Miyazaki M. Effect of olmesartan medoxomil on atherosclerosis: clinical implications of the emerging evidence. Am J Cardiovasc Drugs. 6(6), 363-366, 2006. (Review)

117.: Miyazaki M, Takai S, Jin D, Muramatsu M. Pathological roles of angiotensin II produced by mast cell chymase and the effects of chymase inhibition in animal models. Pharmacol Ther. 112(3), 668-676, 2006. (Review)

116.: Miyazaki M, Takai S. Tissue angiotensin II generating system by angiotensin-converting enzyme and chymase. J Pharmacol Sci. 100(5), 391-397, 2006. (Review)

115.: Takai, S, Jin D, Muramatsu M, Miyazaki M. Chymase inhibitor as a novel therapeutic strategy for anti-vascular remodeling. Vasc Dis Prevent. 3, 33-39, 2006. (Review)

2005

114.: Takai S, Kirimura K, Jin D, Muramatsu M, Yoshikawa K, Mino Y, Miyazaki M. Significance of angiotensin II receptor blocker lipophilicities and their protective effect against vascular remodeling. Hypertens Res. 28(7), 593-600, 2005.

113.: Takai S, Jin D, Muramatsu M, Kirimura K, Sakonjo H, Miyazaki M. Eplerenone inhibits atherosclerosis in nonhuman primates. Hypertension. 46(5), 1135-1139, 2005.

112.: Takai S, Jin D, Sakaguchi M, Muramatsu M, Miyazaki M. The regressive effect of an angiotensin II receptor blocker on formed fatty streaks in monkeys fed a high-cholesterol diet. J Hypertens. 23(10), 1879-1886, 2005.

111.: Ebihara N, Funaki T, Murakami A, Takai S, Miyazaki M. Mast cell chymase decreases the barrier function and inhibits the migration of corneal epithelial cells. Curr Eye Res. 30(12), 1061-1069, 2005.

110.: Konno T, Maruichi M, Takai S, Oku H, Sugiyama T, Uchibori T, Nagai A, Kogi K, Ikeda T, Miyazaki M. Effect of chymase on intraocular pressure in rabbits. Eur J Pharmacol. 524(1-3), 132-137, 2005.

109.: Matsuno K, Yamada H, Iwata K, Jin D, Katsuyama M, Matsuki M, Takai S, Yamanishi K, Miyazaki M, Matsubara H, Yabe-Nishimura C. Nox1 is involved in angiotensin II-mediated hypertension: a study in Nox1-deficient mice. Circulation. 112(17), 2677-2685, 2005.

108.: Nishio H, Takai S, Miyazaki M, Horiuchi H, Osawa M, Uemura K, Yoshida K, Mukaida M, Ueno Y, Suzuki K. Usefulness of serum mast cell-specific chymase levels for postmortem diagnosis of anaphylaxis. Int J Legal Med. 119(6), 331-334, 2005.

107.: Kirimura K, Takai S, Jin D, Muramatsu M, Kishi K, Yoshikawa K, Nakabayashi M, Mino Y, Miyazaki M. Role of chymase-dependent angiotensin II formation in regulating blood pressure in spontaneously hypertensive rats. Hypertens Res. 28(5), 457-464, 2005.

106.: Ebihara N, Takai S, Miyazaki M, Murakami A. Mast cell chymase induces conjunctival epithelial cell apoptosis by a mechanism involving degradation of fibronectin. Curr Eye Res. 30(6), 429-435, 2005.

105.: Ibaraki T, Muramatsu M, Takai S, Jin D, Maruyama H, Orino T, Katsumata T, Miyazaki M. The relationship of tryptase- and chymase-positive mast cells to angiogenesis in stage I non-small cell lung cancer. Eur J Cardiothorac Surg. 28(4), 617-621, 2005.

104.: Jin D, Ueda H, Takai S, Okamoto Y, Muramatsu M, Sakaguchi M, Shibahara N, Katsuoka Y, Miyazaki M. Effect of chymase inhibition on the arteriovenous fistula stenosis in dogs. J Am Soc Nephrol. 16(4), 1024-1034, 2005.

103.: Morikawa T, Imanishi M, Suzuki H, Okada N, Okumura M, Konishi Y, Yoshioka K, Takai S, Miyazaki M. Mast cell chymase in the ischemic kidney of severe unilateral renovascular hypertension. Am J Kidney Dis. 45(3), e45-e50, 2005.

102.: Takai S, Jin D, Muramatsu M, Miyazaki M. The role of chymase in vascular remodeling and tissue fibrosis. Curr Hypertens Rev. 1(2), 159-168, 2005. (Review)

101.: Takai S, Miyazaki M.Inhibition of transforming growth factor-β activation is a novel effect of chymase inactivation. Letters in Drug Design Discovery 2(1), 19-22, 2005. (Review)

100.: Takai S, Jin D, Muramatsu M, Miyazaki M. Development of chymase inhibitor as a potent agent for preventing vascular diseases. Inter J Pharmacol. 1(3), 281-286, 2005. (Review)

2004

99.: Takai S, Jin D, Sakaguchi M, Muramatsu M, Ishii K, Kirimura K, Sakonjo H, Miyazaki M. Comparative effects of candesartan and amlodipine in a monkey atherosclerotic model. Hypertens Res. 27(7), 517-522, 2004.

98.: Ebihara N, Funaki T, Takai S, Miyazaki M, Fujiki K, Murakami A. Tear chymase in vernal keratoconjunctivitis. Curr Eye Res. 28(6), 417-420, 2004.

97.: Takai S, Jin D, Sakaguchi M, Miyazaki M. Significant target organs for hypertension and cardiac hypertrophy by angiotensin-converting enzyme inhibitors. Hypertens Res. 27(3), 213-219, 2004.

96.: Maruichi M, Oku H, Takai S, Muramatsu M, Sugiyama T, Imamura Y, Minami M, Ueki M, Satoh B, Sakaguchi M, Miyazaki M, Ikeda T. Measurement of activities in two different angiotensin II generating systems, chymase and angiotensin-converting enzyme, in the vitreous fluid of vitreoretinal diseases: a possible involvement of chymase in the pathogenesis of macular hole patients. Curr Eye Res. 29(4-5), 321-325, 2004.

95.: Maruichi M, Takai S, Sugiyama T, Ueki M, Oku H, Sakaguchi M, Okamoto Y, Muramatsu M, Ikeda T, Miyazaki M. Role of chymase on growth of cultured canine Tenon's capsule fibroblasts and scarring in a canine conjunctival flap model. Exp Eye Res. 79(1), 111-118, 2004.

94.: Okamoto Y, Takai S, Miyazaki M. Effect of chymase-dependent transforming growth factor beta on peritoneal adhesion formation in a rat model. Surg Today. 34(10), 865-867, 2004.

93.: Sakaguchi M, Takai S, Jin D, Okamoto Y, Muramatsu M, Kim S, Miyazaki M. A specific chymase inhibitor, NK3201, suppresses bleomycin-induced pulmonary fibrosis in hamsters. Eur J Pharmacol. 493(1-3), 173-176, 2004.

92.: Okamoto Y, Takai S, Miyazaki M. Significance of chymase inhibition for prevention of adhesion formation. Eur J Pharmacol. 484(2-3), 357-359, 2004.

91.: Tsunemi K, Takai S, Nishimoto M, Jin D, Sakaguchi M, Muramatsu M, Yuda A, Sasaki S, Miyazaki M. A specific chymase inhibitor, 2-(5-formylamino-6-oxo-2-phenyl-1,6- dihydropyrimidine-1-yl)-N-[[3,4- dioxo-1-phenyl-7-(2-pyridyloxy)]-2- heptyl] acetamide (NK3201), suppresses development of abdominal aortic aneurysm in hamsters. J Pharmacol Exp Ther. 309(3), 879-883, 2004.

90.: Jin D, Takai S, Sakaguchi M, Okamoto Y, Muramatsu M, Miyazaki M. An antiarrhythmic effect of a chymase inhibitor after myocardial infarction. J Pharmacol Exp Ther. 309(2), 490-497, 2004.

89.: Takai S, Jin D, Sakaguchi M, Miyazaki M. A single treatment with a specific chymase inhibitor, TY-51184, prevents vascular proliferation in canine grafted veins. J Pharmacol Sci. 94(4), 443-448, 2004.

88.: Soga Y, Takai S, Koyama T, Okamoto Y, Ikeda T, Nishimura K, Miyazaki M, Komeda M. Attenuation of adhesion formation after cardiac surgery with a chymase inhibitor in a hamster model. J Thorac Cardiovasc Surg. 127(1), 72-78, 2004.

87.: Okumura K, Takai S, Muramatsu M, Katayama S, Sakaguchi M, Kishi K, Jin D, Miyazaki M. Human chymase degrades human fibronectin. Clin Chim Acta. 347(1-2), 223-225, 2004.

86.: Takai S, Jin D, Muramatsu M, Okamoto Y, Miyazaki M. Therapeutic applications of chymase inhibitors in cardiovascular diseases and fibrosis. Eur J Pharmacol. 501(1-3), 1-8, 2004. (Review)

85.: Takai S, Jin D, Muramatsu M, Miyazaki M. Chymase as a novel target for the prevention of vascular diseases. Trends Pharmacol Sci. 25(10), 518-522, 2004. (Review)

2003

84.: Fujiyama S, Amano K, Uehira K, Yoshida M, Nishiwaki Y, Nozawa Y, Jin D, Takai S, Miyazaki M, Egashira K, Imada T, Iwasaka T, Matsubara H. Bone marrow monocyte lineage cells adhere on injured endothelium in a monocyte chemoattractant protein-1-dependent manner and accelerate reendothelialization as endothelial progenitor cells. Circ Res. 93(10), 980-989, 2003.

83.: Takai S, Jin D, Sakaguchi M, Katayama S, Muramatsu M, Sakaguchi M, Matsumura E, Kim S, Miyazaki M. A novel chymase inhibitor, 4-[1-([bis-(4-methyl-phenyl)-methyl]- carbamoyl)3-(2-ethoxy-benzyl)-4-oxo- azetidine-2-yloxy]-benzoic acid (BCEAB), suppressed cardiac fibrosis in cardiomyopathic hamsters. J Pharmacol Exp Ther. 305(1), 17-23, 2003.

82.: Takai S, Kim S, Sakonjo H, Miyazaki M. Mechanisms of angiotensin II type 1 receptor blocker for anti-atherosclerotic effect in monkeys fed a high-cholesterol diet. J Hypertens. 21(2), 361-369, 2003.

81.: Jin D, Takai S, Yamada M, Sakaguchi M, Kamoshita K, Ishida K, Sukenaga Y, Miyazaki M. Impact of chymase inhibitor on cardiac function and survival after myocardial infarction. Cardiovasc Res. 60(2), 413-420, 2003.

80.: Takai S, Sakonjo H, Fukuda K, Jin D, Sakaguchi M, Kamoshita K, Ishida K, Sukenaga Y, Miyazaki M. A novel chymase inhibitor, 2-(5-formylamino-6-oxo-2-phenyl-1,6-dihydropyrimidine-1-yl)-N-[[,4-dioxo-1-phenyl- 7-(2-pyridyloxy)]2- heptyl]acetamide (NK3201), suppressed intimal hyperplasia after balloon injury. J Pharmacol Exp Ther. 304(2), 841-844, 2003.

79.: Takai S, Miyazaki M. A novel therapeutic strategy against vascular disorders with chymase inhibitor. Curr Vasc Pharmacol. 1(2), 217-224, 2003. (Review)

78.: Takai S, Miyazaki M. Application of a chymase inhibitor, NK3201, for prevention of vascular proliferation. Cardiovasc Drug Rev. (Cardiovascular Therapeutics) 21(3), 185-198, 2003. (Review)

2002

77.: Tsunemi K, Takai S, Nishimoto M, Yuda A, Hasegawa S, Sawada Y, Fukumoto H, Sasaki S, Miyazaki M. Possible roles of angiotensin II-forming enzymes, angiotensin converting enzyme and chymase-like enzyme, in the human aneurysmal aorta. Hypertens Res. 25(6), 817-822, 2002.

76.: Muramatsu M, Yamada M, Takai S, Miyazaki M. Suppression of basic fibroblast growth factor-induced angiogenesis by a specific chymase inhibitor, BCEAB, through the chymase-angiotensin- dependent pathway in hamster sponge granulomas. Br J Pharmacol. 137(4), 554-560, 2002.

75.: Okamoto Y, Takai S, Miyazaki M. Chymase inhibitor, BCEAB, suppressed peritoneal adhesion formation in hamster. J Surg Res. 107(2), 219-222, 2002.

74.: Okamoto Y, Takai S, Miyazaki M. Oral administration of a novel chymase inhibitor, NK3201, prevents peritoneal adhesion formation in hamster. Jpn J Pharmacol. (J Pharmacol Sci.) 90(1), 94-96, 2002.

73.: Okamoto K, Takai S, Sasaki S, Miyazaki M. Trandolapril reduces infarction area after middle cerebral artery occlusion in rats. Hypertens Res. 25(4), 583-588, 2002.

72.: Okumura K, Jin D, Takai S, Miyazaki M. Beneficial effects of angiotensin-converting enzyme inhibition in adriamycin-induced cardiomyopathy in hamsters. Jpn J Pharmacol. (J Pharmacol Sci.) 88(2), 183-188, 2002.

71.: Sakaguchi H, Takai S, Sakaguchi M, Sugiyama T, Ishihara T, Yao Y, Miyazaki M, Ikeda T. Chymase and angiotensin converting enzyme activities in a hamster model of glaucoma filtering surgery. Curr Eye Res. 24(5), 325-331, 2002.

70.: Nishimoto M, Takai S, Fukumoto H, Tsunemi K, Yuda A, Sawada Y, Yamada M, Jin D, Sakaguchi M, Nishimoto Y, Sasaki S, Miyazaki M. Increased local angiotensin II formation in aneurysmal aorta. Life Sci. 71(18), 2195-2205, 2002.

69.: Jin D, Takai S, Yamada M, Sakaguchi M, Miyazaki M. Beneficial effects of cardiac chymase inhibition during the acute phase of myocardial infarction. Life Sci. 71(4), 437-446, 2002.

68.: Tsunemi K, Takai S, Nishimoto M, Yuda A, Jin D, Sakaguchi M, Sawada Y, Asada K, Kondo K, Sasaki S, Miyazaki M. Lengthy suppression of vascular proliferation by a chymase inhibitor in dog grafted veins. J Thorac Cardiovasc Surg. 124(3), 621-625, 2002.

67.: Shimizu Y, Sakai K, Miura T, Narita T, Tsukagoshi H, Satoh Y, Ishikawa S, Morishita Y, Takai S, Miyazaki M, Mori M, Saito H, Xia H, Schwartz LB. Characterization of 'adult-type' mast cells derived from human bone marrow CD34(+) cells cultured in the presence of stem cell factor and interleukin-6. Interleukin-4 is not required for constitutive expression of CD54, Fc epsilon RI alpha and chymase, and CD13 expression is reduced during differentiation. Clin Exp Allergy. 32(6), 872-880, 2002.

66.: Miyazaki M, Takai S. Anti-atherosclerotic efficacy of olmesartan. J Hum Hypertens. 16 (Suppl 2), S7-S12, 2002.

65.: Okamoto Y, Takai S, Miyazaki M. Chymase inhibitor suppresses adhesion formation in a hamster experimental model. Eur J Pharmacol. 435(2-3), 265-267, 2002.

64.: Okamoto Y, Takai S, Yamada M, Miyazaki M. Chymase inhibitors may prevent postoperative adhesion formation. Fertil Steril. 77(5), 1044-1048, 2002.

63.: Takai S, Miyazaki M. Effect of chymase inhibitor on vascular proliferation. Jpn J Pharmacol. (J Pharmacol Sci.) 90(3), 223-227, 2002. (Review)

62.: Sukenaga Y, Kamoshita K, Takai S, Miyazaki M. Development of the chymase inhibitor as an anti-tissue-remodeling drug: myocardial infarction and some other possibilities. Jpn J Pharmacol. (J Pharmacol Sci.) 90(3), 218-222, 2002. (Review)

61.: Suzuki T, Kaki H, Naya S, Murayama S, Tatsui A, Nagai A, Takai S, Miyazaki M. Recombinant human chymase produced by silkworm-baculovirus expression system: its application for a chymase detection kit. Jpn J Pharmacol. (J Pharmacol Sci.) 90(3), 210-213, 2002. (Review)

60.: Takai S, Miyazaki M.The Role of Chymase in Vascular Proliferation. Drug News Perspect. 15(5), 278-282, 2002. (Review)

2001

59.: Takai S, Jin D, Kirimura K, Fujimoto Y, Miyazaki M. 12-Hydroxyeicosatetraenoic acid potentiates angiotensin II-induced pressor response in rats. Eur J Pharmacol. 418(1-2), R1-R2, 2001.

58.: Takai S, Jin D, Nishimoto M, Sakaguchi M, Kirimura K, Yuda A, Miyazaki M. Cilostazol suppresses intimal formation in dog grafted veins with reduction of angiotensin II-forming enzymes. Eur J Pharmacol. 411(3), 301-304, 2001.

57.: Nishimoto M, Takai S, Kim S, Jin D, Yuda A, Sakaguchi M, Yamada M, Sawada Y, Kondo K, Asada K, Iwao H, Sasaki S, Miyazaki M. Significance of chymase-dependent angiotensin II-forming pathway in the development of vascular proliferation. Circulation. 104(11), 1274-1279, 2001.

56.: Sakaguchi M, Yamamoto D, Takai S, Jin D, Taniguchi M, Baba K, Miyazaki M. Inhibitory mechanism of daphnodorins for human chymase. Biochem Biophys Res Commun. 283(4), 831-836, 2001.

55.: Takai S, Jin D, Nishimoto M, Yuda A, Sakaguchi M, Kamoshita K, Ishida K, Sukenaga Y, Sasaki S, Miyazaki M. Oral administration of a specific chymase inhibitor, NK3201, inhibits vascular proliferation in grafted vein. Life Sci. 69(15), 1725-1732, 2001.

54.: Takao K, Takai S, Ishihara T, Mita S, Miyazaki M. Isolation of chymase complexed with physiological inhibitor similar to secretory leukocyte protease inhibitor (SLPI) from hamster cheek pouch tissues. Biochim Biophys Acta.-Proteins and Proteomics 1545(1-2), 146-152, 2001.

53.: Iwamoto Y, Song K, Takai S, Yamada M, Jin D, Sakaguchi M, Ueda H, Katsuoka Y, Miyazaki M. Multiple pathways of angiotensin I conversion and their functional role in the canine penile corpus cavernosum. J Pharmacol Exp Ther. 298(1), 43-48, 2001.

52.: Nishimoto M, Takai S, Sawada Y, Yuda A, Kondo K, Yamada M, Jin D, Sakaguchi M, Asada K, Sasaki S, Miyazaki M. Chymase-dependent angiotensin II formation in the saphenous vein versus the internal thoracic artery. J Thorac Cardiovasc Surg. 121(4), 729-734, 2001.

51.: Yamada M, Ueda M, Naruko T, Tanabe S, Han YS, Ikura Y, Ogami M, Takai S, Miyazaki M. Mast cell chymase expression and mast cell phenotypes in human rejected kidneys. Kidney Int. 59(4), 1374-1381, 2001.

50.: Takai S, Sakonjo H, Miyazaki M. Beneficial effect of trandolapril on the lifespan of a severe hypertensive model. Hypertens Res. 24(5), 559-564, 2001.

49.: Takai S, Sakaguchi M, Jin D, Yamada M, Kirimura K, Miyazaki M. Different angiotensin II-forming pathways in human and rat vascular tissues. Clin Chim Acta. 305(1-2), 191-195, 2001.

48.: Jin D, Takai S, Yamada M, Sakaguchi M, Yao Y, Miyazaki M. Possible roles of cardiac chymase after myocardial infarction in hamster hearts. Jpn J Pharmacol. (J Pharmacol Sci.) 86(2), 203-214, 2001.

47.: Takai S, Jin D, Sakaguchi M, Kirimura K, Miyazaki M. An orally active chymase inhibitor, BCEAB, suppresses heart chymase activity in the hamster. Jpn J Pharmacol. (J Pharmacol Sci.) 86(1), 124-126, 2001.

46.: Miyazaki M, Takai S. Local angiotensin II-generating system in vascular tissues: the roles of chymase. Hypertens Res. 24(3), 189-193, 2001. (Review)

2000

45.: Jin D, Takai S, Yamada M, Sakaguchi M, Miyazaki M. The functional ratio of chymase and angiotensin converting enzyme in angiotensin I-induced vascular contraction in monkeys, dogs and rats: Jpn J Pharmacol. (J Pharmacol Sci.) 84(4), 449-454, 2000.

44.: Sakaguchi M, Takai S, Jin D, Yamada M, Miyazaki M. Characteristics of monkey tryptase purified from cheek pouch vascular tissues. Jpn J Pharmacol. (J Pharmacol Sci.) 84(4), 375-380, 2000.

43.: Yuda A, Takai S, Jin D, Sawada Y, Nishimoto M, Matsuyama N, Asada K, Kondo K, Sasaki S, Miyazaki M. Angiotensin II receptor antagonist, L-158,809, prevents intimal hyperplasia in dog grafted veins. Life Sci. 68(1), 41-48, 2000.

42.: Yao YL, Ishihara T, Takai S, Miyazaki M, Mita S. Association between the expression of mast cell chymase and intraperitoneal adhesion formation in mice. J Surg Res. 92(1), 40-44, 2000.

41.: Takai S, Sakaguchi M, Jin D, Miyazaki M. A new method for simultaneous measurements of mast cell proteases in human vascular tissue. Clin Exp Pharmacol Physiol. 27(9), 700-704, 2000.

40.: Nakakubo H, Morita M, Imada T, Takai S, Shiota N, Miyazaki M, Nakamura N. Functional reconstitution of an active recombinant human chymase from Pichia pastoris cell lysate. Yeast. 16(15), 1387-1396, 2000.

39.: Nakakubo H, Fukuyama H, Nakajima M, Imada T, Uno S, Shiota N, Takai S, Miyazaki M, Nakamura N. Secretory production of recombinant human chymase as an active form in Pichia pastoris. Yeast. 16(4), 315-323, 2000.

38.: Takai S, Sumi S, Aoike M, Sakaguchi M, Itoh Y, Jin D, Matsumura E, Miyazaki M. Characterization of recombinant human chymase expressed in Escherichia coli. Jpn J Pharmacol. (J Pharmacol Sci.) 82(2), 144-149, 2000.

37.: Ahn K, Takai S, Pawankar R, Kuramasu A, Ohtsu H, Kempuraj D, Tomita H, Iida M, Matsumoto K, Akasawa A, Miyazaki M, Saito H. Regulation of chymase production in human mast cell progenitors. J Allergy Clin Immunol. 106(2), 321-328, 2000.

36.: Takai S, Yuda A, Jin D, Nishimoto M, Sakagichi M, Sasaki S, Miyazaki M. Inhibition of chymase reduces vascular proliferation in dog grafted veins. FEBS Lett. 467(2-3), 141-144, 2000.

35.: Miyazaki M, Takai S. Role of chymase on vascular proliferation. J Renin Angiotensin Aldosterone Syst. 1(1), 23-26, 2000. (Review)

1999

34.: Takao K, Takai S, Ishihara T, Mita S, Miyazaki M. Inhibition of human chymase by suramin. Jpn J Pharmacol. (J Pharmacol Sci.) 81(4), 404-407, 1999.

33.: Takai S, Jin D, Sakaguchi M, Miyazaki M. Chymase-dependent angiotensin II formation in human vascular tissue: Circulation. 100(6), 654-658, 1999.

32.: Tsutsumi Y, Matsubara H, Masaki H, Kurihara H, Murasawa S, Takai S, Miyazaki M, Nozawa Y, Ozono R, Nakagawa K, Miwa T, Kawada N, Mori Y, Shibasaki Y, Tanaka Y, Fujiyama S, Koyama Y, Fujiyama A, Takahashi H, Iwasaka T. Angiotensin II type 2 receptor overexpression activates the vascular kinin system and causes vasodilation. J Clin Invest. 104(7), 925-935, 1999.

31.: Miyazaki M, Sakonjo H, Takai S. Anti-atherosclerotic effects of an angiotensin converting enzyme inhibitor and an angiotensin II antagonist in Cynomolgus monkeys fed a high-cholesterol diet. Br J Phamacol. 128(3), 523-529, 1999.

30.: Takai S, Jin D, Kirimura K, Ikeda J, Sakaguchi M, Baba K, Fujita T, Miyazaki M. Effects of a lipoxygenase inhibitor, panaxynol, on vascular contraction induced by angiotensin II. Jpn J Pharmacol. (J Pharmacol Sci.) 80(1), 89-92, 1999.

29.: Miyazaki M, Shiota N, Sakonjo H, Takai S. Angiotensin II type 1 receptor antagonist, TCV-116, prevents neointima formation in injured arteries in the dog. Jpn J Pharmacol. (J Pharmacol Sci.) 79(4), 455-460, 1999.

28.: Shiota N, Okunishi H, Takai S, Mikoshiba I, Sakonjo H, Shibata N, Miyazaki M. Tranilast suppresses vascular chymase expression and neointima formation in balloon-injured dog carotid artery. Circulation. 99(8), 1084-1090, 1999.

27.: Song K, Kanehara H, Takai S, Shiota N, Wada T, Inada Y, Miyazaki M. Inhibition of the angiotensin II Type 1 receptor by TCV-116: quantitation by in vitro autoradiography. Jpn J Pharmacol. (J Pharmacol Sci.) 79(2), 131-139, 1999.

26.: Takai S, Sakaguchi M, Jin D, Baba K, Miyazaki M. Effects of daphnodorin A, daphnodorin B and daphnodorin C on human chymase-dependent angiotensin II formation. Life Sci. 64(21), 1889-1896, 1999.

25.: Takai S, Jin D, Sakaguchi M, Kirimura K, Ikeda J, Baba K, Fujita T, Miyazaki M. Effects of a new 12-lipoxygenase inhibitor, daphnodorin A, on angiotensin II-induced vascular contraction in hamster. Prostaglandins Leukot Essent Fatty Acids. 60(2), 135-138, 1999.

24.: Miyazaki M, Wada T, Shiota N, Takai S. Effect of an angiotensin II receptor antagonist, candesartan cilexetil, on canine intima hyperplasia after balloon injury. J Hum Hypertens. 13 Suppl 1, S21-S25, 1999.

23.: Takao K, Takai S, Shiota N, Song K, Nishimura K, Ishihara T, Miyazaki M. Lack of effect of carbohydrate depletion on some properties of human mast cell chymase. Biochim Biophys Acta.-General Subjects. 1427(1), 74-81, 1999.

22.: Miyazaki M, Takai S. Antiatherosclerotic effect of alacepril, an angiotensin-converting enzyme inhibitor, in monkeys fed a high-cholesterol diet. Hypertens Res. 22(1), 49-54, 1999.

1998

21.: Jin D, Takai S, Shiota N, Miyazaki M. Tranilast, an anti-allergic drug, possesses antagonistic potency to angiotensin II. Eur J Pharmacol. 361(2-3), 199-205, 1998.

20.: Shiota N, Fukamizu A, Okunishi H, Takai S, Murakami K, Miyazaki M. Cloning of the gene and cDNA for hamster chymase 2, and expression of chymase 1, chymase 2 and angiotensin-converting enzyme in the terminal stage of cardiomyopathic hearts. Biochem J. 333 (Pt 2), 417-424, 1998.

19.: Eda M, Ashimori A, Akahoshi F, Yoshimura T, Inoue Y, Fukaya C, Nakajima M, Fukuyama H, Imada T, Takai S, Shiota N, Miyazaki M, Nakamura N. Peptidyl human heart chymase inhibitors. 2. Discovery of highly selective difluoromethylene ketone derivatives with Glu at P3 site. Bioorg Med Chem Lett. 8(8), 919-924, 1998.

18.: Eda M, Ashimori A, Akahoshi F, Yoshimura T, Inoue Y, Fukaya C, Nakajima M, Fukuyama H, Imada T, Takai S, Shiota N, Miyazaki M, Nakamura N. Peptidyl human heart chymase inhibitors. 1. Synthesis and inhibitory activity of difluoromethylene ketone derivatives bearing P' binding subsites. Bioorg Med Chem Lett. 8(8), 913-918, 1998.

17.: Takai S, Shiota N, Jin D, Miyazaki M. Chymase processes big-endothelin-2 to endothelin-2-(1-31) that induces contractile responses in the isolated monkey trachea. Eur J Pharmacol. 358(3), 229-233, 1998.

16.: Takai S, Shiota N, Jin D, Miyazaki M. Functional role of chymase in angiotensin II formation in human vascular tissue. J Cardiovasc Pharmacol. 32(5), 826-833, 1998.

15.: Takai S, Jin D, Hara K, Takami H, Fujita T, Miyazaki M. 12-Hydroxyeicosatetraenoic acid directly potentiates angiotensin II-induced vascular contraction. Eur J Pharmacol. 358(2), 161-164, 1998.

14.: Song K, Shiota N, Takai S, Takashima H, Iwasaki H, Kim S, Miyazaki M. Induction of angiotensin converting enzyme and angiotensin II receptors in the atherosclerotic aorta of high-cholesterol fed Cynomolgus monkeys. Atherosclerosis. 138(1), 171-182, 1998.

13.: Jin D, Takai S, Shiota N, Miyazaki M. Roles of vascular angiotensin converting enzyme and chymase in two-kidney, one clip hypertensive hamsters. J Hypertens. 16(5), 657-664, 1998.

12.: Yamamoto D, Shiota N, Takai S, Ishida T, Okunishi H, Miyazaki M. Three-dimensional molecular modeling explains why catalytic function for angiotensin-I is different between human and rat chymases. Biochem Biophys Res Commun. 242(1), 158-163, 1998.

1997

11.: Jin D, Song K, Oka Y, Takai S, Shiota N, Miyazaki M. Pharmacological profiles of a novel non-peptide angiotensin II type I receptor antagonist HR720 in vitro and in vivo. Jpn J Pharmacol. (J Pharmacol Sci.) 75(3), 259-266, 1997.

10.: Takai S, Shiota N, Sakaguchi M, Muraguchi H, Matsumura E, Miyazaki M. Characterization of chymase from human vascular tissues. Clin Chim Acta. 265(1), 13-20, 1997.

9.: Takai S, Shiota N, Kobayashi S, Matsumura E, Miyazaki M. Induction of chymase that forms angiotensin II in the monkey atherosclerotic aorta. FEBS Lett. 412(1), 86-90, 1997.

8.: Niwata S, Fukami H, Sumida M, Ito A, Kakutani S, Saitoh M, Suzuki K, Imoto M, Shibata H, Imajo S, Kiso Y, Tanaka T, Nakazato H, Ishihara T, Takai S, Yamamoto D, Shiota N, Miyazaki M, Okunishi H, Kinoshita A, Urata H, Arakawa K. Substituted 3-(phenylsulfonyl)-1-phenylimidazolidine-2,4-dione derivatives as novel nonpeptide inhibitors of human heart chymase. J Med Chem. 40(14), 2156-2163, 1997.

7.: Shiota N, Jin D, Takai S, Kawamura T, Koyama M, Nakamura N, Miyazaki M. Chymase is activated in the hamster heart following ventricular fibrosis during the chronic stage of hypertension. FEBS Lett. 406(3):301-304, 1997.

6.: Shiota N, Fukamizu A, Takai S, Okunishi H, Murakami K, Miyazaki M. Activation of angiotensin II-forming chymase in the cardiomyopathic hamster heart. J Hypertens. 15(4), 431-440, 1997.

1996

5.: Takai S, Shiota N, Yamamoto D, Okunishi H, Miyazaki M. Purification and characterization of angiotensin II-generating chymase from hamster cheek pouch. Life Sci. 58(7), 591-597, 1996.

4.: Takai S, Song K, Tanaka T, Okunishi H, Miyazaki M. Antinociceptive effects of angiotensin-converting enzyme inhibitors and an angiotensin II receptor antagonist in mice. Life Sci. 59(21), PL331-PL336, 1996.

1994

3.: Song K, Miyazaki M, Okunishi H, Ishii K, Takai S, Shiota N, Kim S, Mendelsohn FA. Localization and quantitation of active renin in monkey kidney by radioinhibitor binding and in vitro autoradiography. Am J Hypertens. 7(6), 529-535, 1994.

1992

2.: Fujimoto Y, Takai S, Matsuno K, Sumiya T, Nishida H, Sakuma S, Fujita T. Effect of tert-butyl hydroperoxide on cyclooxygenase and lipoxygenase metabolism of arachidonic acid in rabbit platelets. Prostaglandins Leukot Essent Fatty Acids. 47(4), 259-264, 1992.

1991

1.: Fujimoto Y, Kondo Y, Nakajima M, Takai S, Sakuma S, Fujita T. Stimulation of prostaglandin synthesis in rabbit gastric antral mucosal slices by desferrioxamine in vitro. Biochem Int. 24(1), 33-42, 1991.